Clonidine
Brand names: Clonidine
At a glance
- Medicare prescriptions, 2024
- 255,286
- Medicare drug cost
- $29.6M
- Average cost per prescription
- $116
- Clinicians who prescribed it
- 11,977
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
NEXICLON XR is indicated in the treatment of hypertension. NEXICLON XR may be employed alone or concomitantly with other antihypertensive agents.
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 26.7%
- Family Medicine 21.7%
- Nurse Practitioners 12.4%
- Cardiology 12.3%
- Nephrology (Kidney) 10.4%
- Interventional Cardiology 4.4%
- Physician Assistants 2.9%
- Geriatric Medicine 2.7%
- General Practice 1.0%
- Cardiac Electrophysiology 0.8%
- Psychiatry 0.6%
- Hospitalist 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 9% from 2019 to 2024.
Biggest change by state since 2019
- Arkansas +14%
- Mississippi +12%
- Alabama +12%
- Arizona +6%
- Louisiana +4%
- Pennsylvania (smallest change) −27%
- Illinois (smallest change) −25%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Alembic Pharmaceuticals Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 0.05 mg | brown round tablet, 5 mm | 51 |
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 0.1 mg | white round tablet, 7 mm | CL |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.1 mg | brown oval tablet, 7 mm, scored to split in 2 | L167 |
Rosemont Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 0.17 mg | white oval tablet, 13 mm, scored to split in 2 | NP2 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $713 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Athena Bioscience, LLC $713
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Mar 2026 · Teva Pharmaceuticals USA, Inc · Class II
CGMP Deviations: use of an unapproved raw material - Jun 2022 · Mayne Pharma Inc · Class II
Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint. - Oct 2021 · Teva Pharmaceuticals USA · Class III
Failed Impurities/Degradation Specifications
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.